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We characterized the virologic failure after an initially successful 48-week course of antiretroviral therapy among
HIV/AIDS patients in a retrospective cohort study involving patients from Santos, Brazil. Patients with plasma HIV
RNA below 500 copies/mL for 48 weeks were included. Variables analyzed included gender, age, level of education,
marital status, mode of HIV acquisition, viral load, and CD4 cell count upon admission. There were 4,909 patients
registered with the clinic, of which 669 patients met all the inclusion criteria (41.6% female and 58.4% male). Only
27.5% of the patients maintained undetectable viral loads during up to one year of follow-up. After 48 weeks,
virologic failure occurred earlier in females and in patients first treated with an antiretroviral regimen other than
highly active antiretroviral therapy. Patients who were married or had a steady partner experienced virologic
failure later than did those who were separated or widowed. The percentage of public health clinic patients who
maintain undetectable viral loads for a period of over a year is much lower than that observed among patients
enrolled in clinical trials. Females, individuals in unstable relationships, single individuals and widowed individuals
should be given special attention in order to improve durability of viral suppression.
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The treatment of HIV-positive patients with highly active
antiretroviral therapy (HAART), has resulted in a dramatic
decrease in AIDS-related morbidity and mortality, as has been
demonstrated by various authors [1-4]. Previous studies
indicate that this combined therapy decreases plasma levels
of HIV RNA, as seen in two separate studies reporting levels
of less than 50 copies/mm3 in 60% of patients and less than
500 copies/mm3 in 90% of patients [5-7]. However, since
antiretroviral therapy involves regimens that are often complex
and present side effects in a great number of patients, it is
difficult to achieve a high degree of adherence to treatment,
which is required in order to maintain viral suppression
[5,6,8]. Taking these difficulties into consideration, it is clear
that the success of HAART regimens depends on the
quality of health services. In addition, these regimens might
be less efficient, in various forms, at specialized non-
university clinical outpatient facilities that do not engage
in clinical trials [9]. In addition, in contrast with developed
countries where HAART is available to HIV-positive
patients, this therapy is unavailable in most developing
countries, where over 90% of these patients reside [10].
Before the HAART era, various studies revealed a lower
survival rate among HIV-positive ethnic minorities, women,
intravenous drug users and individuals of low socioeconomic
status [11-13]. Some studies, carried out after the advent of
HAART, have clearly shown that the sustained viral
suppression rate is lower in outpatients evaluated in a large
urban clinic than in those monitored in clinical trials [10]. The
effect that demographic differences have on the success of
HAART is less evident.
Santos is a coastal city located in the south of the state of
Sao Paulo, Brazil, and has a population of 440,000 inhabitants.
Santos is a major tourist destination and the largest port in
Latin America. People from various regions of Brazil and the
rest of the world visit the city. Since the beginning of the
AIDS epidemic in Brazil, Santos has been known as a city
with one of the highest AIDS prevalence rates.
Santos was the first city in the country to provide free
protease inhibitors (PIs) to its patients and has been
distributing them without restriction since February of 1996.
Subsequently, the National STD/AIDS Program of the Brazilian
Ministry of Health began to provide universal access to all
HAART medications [14,15]. This policy has resulted in
significantly lower AIDS-related mortality and morbidity15 as
seen in other countries [1,4]. Comprehensive studies of the
characteristics related to antiretroviral therapy adherence have
been carried out in Brazil. However, some of those studies did
not employ objective markers of the evolution of the disease,
such as CD4 and CD8 T-lymphocyte counts and HIV RNA
plasma levels, to evaluate the consequent therapeutic response
[16,17]. In the current study we attempted to characterize the
virologic failure after an initial 48-week virologic success
among patients on antiretroviral therapy in the city of Santos.
Material and Methods
This retrospective cohort study involved monitored
patients registered with the Santos Referral Center for AIDS
(CRAIDS), in order to assess the occurrence of virologic
failure in individuals undergoing antiretroviral treatment.
CRAIDS is the only outpatient clinic for adults with HIV/
AIDS in the city of Santos. The study sample comprised
patients treated with any type of antiretroviral regimen
between 1997 and 2003. Those whose plasma HIV RNA levels
remained below 500 copies/mL for at least 48 weeks were
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included. Data from routine laboratory tests required in the
clinic were used in this study, according to the instructions
from the Ministry of Health that recommends virologic testing
every four months. The criterion used in the definition of
virologic failure was plasma HIV RNA higher than 500 copies/
mL after inclusion in the study. Patient’s data were collected
up to December 31, 2003. Sociodemographic variables (gender,
age bracket, level of education and marital status), behavioral
variables (mode of HIV acquisition) and markers of evolution
(viral load and number of CD4 cells upon admission) were
included as possible explanatory variables for virologic failure.
The antiretroviral therapy was analyzed in a comprehensive
way (HAART and non-HAART), with no distinctions being
made between specific regimens. Data regarding adherence
to treatment were also not considered. Data collection was
carried out through the review of patient medical charts on
file at CRAIDS. The information was initially registered on a
pre-structured questionnaire. The statistical analysis was
performed by entering data into a database constructed using
the Epi Info program, version 3.3.0. Initially, we carried out a
descriptive analysis of the general characteristics of the
population studied regarding the occurrence of virologic
failure and exposure to the explanatory variables proposed.
The quantitative and qualitative variables were categorized
using interpretative criteria based on biological or
epidemiological rationale. Survival curves were calculated
using the Kaplan-Meier product-limit estimate in order to
determine the general survival function, and the curves were
constructed according to the inclusion stratum in the study
of the explanatory variables considered. In this phase, we
observed whether the curves overlapped. If they did not
overlap, they would comply with the visual assumptions of
proportionality over time. The different variables were not
adjusted to one another and were compared using the log-
rank test, observed for each stratum of the respective variables.
CD4 and CD8 T-lymphocyte subpopulation counting was
performed by flow cytometry using the FACSCount system
(Becton Dickinson, San Jose, CA, USA). HIV-1 viral load was
performed using the NASBA technique (Biomerieux, Marcy
l’Etoile, France). The laboratory belongs to the Santos
Municipal Secretary of Health and has an operating agreement
with the Brazilian Ministry of Health, which is responsible for
quality control.
Results
There were 4,909 patients registered with the clinic, of
which 669 patients remained with HIV RNA viral load below
500 copies/mL for at least 48 weeks. This represented the
27.5% of all CRAIDS patients undergoing antiretroviral
therapy and presenting viral loads that remained lower than
500 copies/mL for over 48 weeks.
Of the 669 patients studied, 278 (41.6%) were female and
381 (58.4%) were male (Table 1). The mean age was 42 years,
and the majority of patients fell into one of two age brackets:
21 to 40 (47.7%); and 41 to 60 (46.9%) (Table 1). A total of 233
patients (34.8%) were married. The most common mode of
exposure to HIV, regardless of gender, was through
unprotected sex with multiple partners or with a partner who
had multiple partners, accounting for 421 cases (62.9%). In
general, females presented lower levels of education, although
education was found not to be related to virologic failure. A
total of 52.9% of females, in contrast to 43.5% of males, had
either no schooling or less than 8 years of schooling. In
addition, only 28.4% of females had completed high school,
compared with 35.3% of males. However, there was no
significant difference between males and females in terms of
higher education. All of these data, grouped by gender, can
be observed in Table 1.
Baseline CD4 counts revealed 0-200 cells/mm3 in 229
patients (34.3%); 201-350 cells/mm3 in 155 (23.2%); 351-500
cells/mm3 in 112 (16.8%); and >500 cells/mm3 in 171 (25.6%).
Baseline viral loads were lower than 10,000 copies/mm3 in 461
(68.9%) of the patients; between 10,001 and 100,000 copies/
mm3 in 139 (20.8%); and greater than 100,001 copies/mm3 in 69
(10.3%).
Initial antiretroviral regimens used by the patients were as
follows: 1 NRTI, by 10.4% (29) of the females and 3.6% (14) of
the males; 2 NRTIs, 36.7% (102) of the females and 29.2%
(114) of the males; 3 NNRTIs, 1.4% (4) of the females and 1.0%
(4) of the males; 2 NRTIs plus 1 NNRTI, 26.3% (73) of the
females and 25.6% (100) of the males; 2 NRTI plus 1 PI, 25.2%
(70) of the females and 40.7% (159) of the males. When we
grouped patients by the type of antiretroviral therapy used,
we observed that 404 (60.4%) of the patients used HAART.
The 265 (39.6%) that used non-HAART drugs, which is not
recommended by current guidelines, nevertheless maintained
viral loads below 500 copies/mm3 for over twelve months.
Using the Kaplan-Meier test to analyze the durability of
viral suppression, defined as an undetectable viral load, after
an initially successful 48-week course of antiretroviral therapy,
we observed that virologic failure occurred earlier in females
than in males (Figure 1).
Using the same test to evaluate only those patients initially
receiving HAART, we observed that a smaller difference
between female/male regarding the occurrence of virologic
failure, with a tendency towards equality between 60 and 70
months of follow-up (Figure 2).
In our study sample, the baseline CD4 values and viral
load did not present Kaplan-Meier correlations with the
durability of viral suppression.
We found that patients who were first treated with 1 NRTI,
2 NRTIs or 3 NRTIs presented less viral suppression durability
over time than did those who were first treated with 2 NRTIs +
1 NNRTI or with 1 PI (Figure 3).
The only sociodemographic variable found to affect the
duration of viral suppression was being married or having a
steady partner. Among patients for whom the initial therapy
was HAART, those who were married or had a steady partner
experienced virologic failure later than did those who were
separated or widowed (Figure 4).
Virologic Failure After an Initial 48-Week Success
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Table 1. Sociodemographic profile of the patients in relation to the ocurrence of virologic failure.
Figure 1. Duration of viral suppression, by gender, as
estimated using the Kaplan-Meier test, in 669 HIV-positive
patients treated at the Santos Referral Center for AIDS between
1997 and 2003.
Figure 2. Kaplan-Meier test: duration of viral suppression
prior to virologic failure, by gender, among patients using
HAART (n=404).
Virologic Failure After an Initial 48-Week Success
 
0 10 20 30 40 50 60 70
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
Females
Males
Duration (in months)
A
nt
ire
tr
ov
ira
l t
he
ra
py
 s
uc
ce
ss
 (%
)
Variable Female Male OR p
Age
21 to 40 years 52.9% 147 44.0% 172 NS NS
41 to 60 years 40.6% 113 51.4% 201 1.52 <0.0001
>60 years 6.5% 18 4.6% 18 0.85 0.65
Education
Illiterate/literate 5.8% 16 2.6% 10 NS NS
Elementary school 47.1% 131 43.5% 291 3.55 <0.001
High school 28.4% 79 35.3% 138 2.79 0.01
Higher education 10.1% 28 13.3 52 2.97 0.01
Without information 8.6% 24 7.9 31 NS NS
Marital status
Married/cohabiting 37.8% 105 32.7% 128 NS NS
Widowed/divorced 28.8% 80 17.4% 68 0.7 0.08
Single 25.2% 70 39.1% 153 1.79 0.002
Other 5.0% 14 7.9% 31 1.28 0.08
Without information 3.2% 9 2.8% 11 NS NS
Type of contamination
Injectable drugs 4.3% 12 7.4% 29 -
Multiple partners 25.5% 71 35.8% 140 NS NS
Individual with multiple partners 27.3% 76 34.3% 134 NS NS
Partner HIV/AIDS 37.4% 104 17.4% 68 0.27 >0.0001
Not known 5.4% 15 5.1% 20 NS NS
Initial CD4 (First)
0 to 200 27.5% 76 39.1% 153 NS NS
201 to 350 20.7% 57 25.1% 98 NS NS
351 to 500 21.4% 59 13.6% 53 NS NS
>500 30.4% 84 22.3% 87 NS NS
Initial viral load (First)
0 to 10,000 70.1% 195 68.0% 266 NS NS
10,001 to 100,000 20.1% 56 21.2% 83 NS NS
100,001 to 1,000,000 9.7% 27 10.7% 42 NS NS
Initial medication
Antiretroviral therapy 48.2% 134 33.5% 131 - -
HAART 51.8% 144 66.5% 260 1.85 >0.0001
Total % (n=278) % (n=391)
OR=odds ratio; p=p value; NS=not significant.
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Figure 3. Kaplan-Meier test: duration of viral suppression
prior to virologic failure, by type of antiretroviral therapy
initially used (n=669).
Figure 4. Kaplan-Meier test: duration of viral suppression
prior to virologic failure, by marital status, among the group
of patients receiving HAART.
Discussion
In this retrospective analysis of the effectiveness of
HAART in patients treated at public health clinics, we found
that the proportion of such patients in whom therapeutic
success was achieved was much lower than that found in
patients treated in clinical trials [5,18,19]. However, the results
are similar to the findings reported for public and private urban
clinics in the USA [2], Europe [9] and Brazil [20,21].
In 2004, a study conducted in Brazil involving 211 patients
in 5 public health clinics in Rio de Janeiro, revealed that 44%
of these patients achieved undetectable viral loads within 6
months [20]. However, there are no sequential data regarding
the maintenance of these values. Additional data reported
that the median time to virologic failure was approximately 14
months among Brazilian treatment-naïve patients [21], and
presumably, antiretroviral treatment failure rates are higher
among those receiving sequential treatment.
In the current study, we detected that only 27.5% of the
patients maintained viral loads below detection limits for one
year. It is of note that these data represent patients who
achieved this objective with the first antiretroviral therapy
administered. This fact is certainly extremely relevant and
alarming, since a high risk of failure is expected from these
patients over time, in addition to the high rate of primary
resistance recently described for the city of Santos, which is
approximately 36% among patients with recent infection, and
the high rates of non-B clade, which is around 50% [22].
Concerning other factors related to virologic failure, we
observed that being a female, being single and being widowed
were related to higher rates of failure. In a comprehensive
study of adherence carried out in Brazil [16,17], gender-related
alterations in adherence were not observed, although marital
status was not assessed in those studies. We find our
observation extremely important, since it places females in a
situation of greater vulnerability, which might have been
overlooked in the surveys conducted by other authors. Taking
into consideration the fact that, although the levels of HIV-1
RNA are usually lower in women than in men, the rates of
progression to AIDS are similar between men and women [23],
in addition to the theoretical possibility of pregnancy, we
believe this observation to be highly relevant. Furthermore, it
has been suggested that females are at a higher risk of
presenting adverse effects [9], a fact that was not confirmed
in the current study. It is interesting to note that there was a
trend for women to be treated more frequently without
HAART, with fewer PIs, and that the difference in virologic
response among men and women is not present when HAART
is used. Other studies are necessary in order to provide more
accurate information that would confirm the tendency of
higher virologic failure among women. We found that patients
in stable marital relationships maintain undetectable viral loads
for a longer period of time, probably reflecting more propitious
conditions for the use of this medication in patients with stable
family relationships. We did not observe any difference among
individuals of different educational levels in terms of viral
suppression, a finding that is in contrast with those of other
studies conducted in Brazil [21]. This suggests that despite
the fact that, in Brazil, HIV tends to affect individuals of lower
socioeconomic status, antiretroviral therapy can be used
appropriately, provided these patients are properly instructed
and motivated. It is important to realize that, in contrast to the
findings of other studies [21], viral suppression, in our study
sample, was not found to be influenced by the CD4 nadir.
This probably reflects the potency of the new antiretroviral
regimens and their introduction in the period prior to the
analysis of these data. Finally and not surprisingly, the use of
HAART, understood here as the triple therapy with 2 NRTIs
plus 1 NNRTI or with 1 PI, was associated with greater viral
suppression durability after the initial 48 weeks of viral
suppression, to the detriment of other regimens that are
unfortunately still in use, such as the double-NRTI or triple-
NRTI regimens. This finding suggests that even in the initial
presence of viral suppression with less potent regimes, it may
be worth increasing the potency of the antiretroviral scheme
in order to prevent an earlier virologic failure.
We acknowledge that the retrospective nature of this study
may prevent more definitive conclusions, especially due to
the lack of information on adherence to treatment. However
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we believe that the design of future prospective studies may
take into account the information presented here.
In conclusion, our data suggest that the percentage of
public health clinic patients who maintain undetectable viral
loads for a period of over a year is much lower than that
observed among patients enrolled in clinical trials. However,
it is similar to those observed among patients treated at other
urban clinics. Females, individuals in unstable relationships,
single individuals and widowed individuals should be given
special attention in order to improve and make the antiretroviral
therapy more appropriate, thus increasing the durability of
viral suppression. Further studies should be conducted in
order to better understand the differences observed between
various locations, so that effective measures can be taken to
adapt the therapy in order to improve and prolong antiretroviral
response, consequently decreasing morbidity and mortality.
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